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Abstract
Background: Tumor-induced lymphangiogenesis plays a crucial role in metastasis and tumor progression.
However, the significance of intratumoral lymphovascular density (I-LVD) and peritumoral lymphovascular density
(P-LVD) has been controversial in gastric cancer. The purpose of this study was to investigate the differences of
clinicopathologic characteristics with respect to I-LVD and P-LVD in gastric cancer.
Methods: Samples of I-LVD and P-LVD from 66 patients who had undergone radical gastrectomy for gastric cancer
were assessed after staining with D2-40, an immunostaining marker for lymphatic endothelium. The mean number
of lymphatic vessels in three hotspots was calculated in intratumoral and peritumoral areas.
Results: The peritumoral lymphatics were enlarged with dilated lumens compared to the intratumoral lymphatics.
I-LVD was positively correlated with diffuse gastric cancer subtype, tumor stage, lymphovascular invasion, tumor
node metastasis stage, and overall survival (P <0.05). P-LVD was associated with lymphovascular invasion, node
stage, and disease-free survival (P <0.05).
Conclusions: We conclude that P-LVD had an important role in lymph node metastasis, while I-LVD was more
associated with depth of tumor invasion. However, both LVDs contributed to gastric cancer progression and
prognosis.
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Background
In 2012, gastric cancer was responsible for 723,000 deaths
and was ranked as the world’s third leading cause of cancer
mortality [1]. Gastric cancer was also the second most
common malignancy in Korea [2]. Regional lymph nodes
are the most common site of tumor spread and lymph node
metastasis is a major prognostic factor in gastric carcin-
omas. Thus, understanding the mechanism of lymphatic
metastasis represents a crucial step that could result in a
new therapeutic target in the treatment of gastric cancer.
Recent studies have suggested that lymphangiogenesis,
the formation of new lymphatic vessels induced by tumors,
is directly correlated with the extent of metastasis of solid
tumors in lymph nodes [3–8]. Lymphatic vessel density
(LVD) is a quantitative measure of tumor lymphangiogen-
esis and is measured by directly counting lymphatic vessels.
It has been reported that high LVD in gastric cancer
correlates with regional lymph node metastasis and poor
prognosis [9–11]. However, in these studies, the effect of
lymphangiogenesis associated with intratumoral lymphatics
or peritoumoral lymphatics was not evaluated.
There is considerable debate about the roles of intratu-
moral versus peritumoral lymphatics in the pathology of
the primary tumor [3, 5, 8, 12–16]. It is well established
that peritumoral lymphatics are predominantly respon-
sible for providing access to cancer cells during metasta-
sis [16]. Peritumoral-LVD (P-LVD) was associated with
lymph node metastases of tumors, for example, of the
breast, prostate, and uterine cervix [3, 5, 8]. In contrast,
intratumoral-LVD (I-LVD) was predictive of lymphatic
metastasis in cancers of other organs, including papillary
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carcinoma of the thyroid and squamous cell carcinoma
of the head, neck, esophagus, and oral cavity [12–15].
Nonetheless, the role of different lymphatics in gastric
cancer is unclear and remains controversial. Some re-
searchers have concluded that P-LVD is more important
than I-LVD [17–19], while others present conflicting
results [20–23].
Here, we investigated the clinical significance of I-LVD
and P-LVD in gastric cancer to evaluate their role as risk




Three hundred and sixty-five patients with gastric can-
cer underwent curative radical gastrectomy at Severance
Hospital of Yonsei University, Seoul, Korea during the
period of June 2005 to December 2005. This is the lon-
gest follow-up period that we are aware of in which
complete data, including lymphovascular invasion (LVI)
status, was collected. For preliminary data to test a cor-
relation between the location of lymphatics and clinico-
pathologic parameters, we selected 66 cases from the
365 cases with their Tumor, Node, Metastasis (TNM)
stages according to Lauren’s classification. None of the
patients these specimens came from had received pre-
operative chemotherapy or radiotherapy. The study
population consisted of 47 men (71 %) and 19 women
(19 %). The patients’ ages ranged from 23 to 81 years
and the average age at diagnosis was 59 years. There
were 18 cases of early gastric cancer and 48 cases of ad-
vanced gastric cancer. The histological stage was based
on classification system cited in the American Joint
Committee on Cancer’s Staging Manual, 7th edition.
Other clinical features assessed and are summarized in
Table 1. Patients were followed up clinically for at least
five years after surgery, except in mortality cases. The
follow-up time ranged from 3 to 69 months, with an
average follow-up time of 55 months. The current study
was approved by the Institutional Review Board of
Severance Hospital, Yonsei University (4-2012-0427).
Immunohistochemistry and assessment of LVD
Tumor specimens were prospectively collected at the tis-
sue bank of the hospital after operation. Immunohisto-
chemical staining was performed on 4-μm thick samples
that had been fixed in 10 % formalin and embedded in
paraffin. The paraffin was solubilized and removed with
xylene and the sections were rehydrated. Endogenous
peroxidase was blocked with 3 % hydrogen peroxide for
10 min. Immunoperoxidase staining was performed
using a streptavidin-biotin peroxidase method. Antigen
retrieval was performed using 0.01 M sodium citrate
buffer through microwave processing for D2-40
antibody, an immunostaining marker for lymphatic
endothelium. Non-specific antibody binding was blocked
with normal rabbit serum. The slides were incubated
with primary antibodies for D2-40 (1:100 diluted; DAKO
Cytomation, Glostrup, Denmark). Antigen-antibody re-
action was visualized using 3-amino-9-ethylcarbazole
substrate (AEC, NeoMarkers, Fremont, CA, USA) as
chromogen. The slides were counterstained with Mayer’s
hematoxylin and mounted. The immune-staining of all
66 selected formalin fixed paraffin embedded tissues
were performed in a way under the same conditions.
I-LVD was measured at the tumor center while P-LVD
was measured in the periphery within 2 mm of tumors
adjacent to the invasion front. The two values were
assessed separately. LVD was detected by immunostain-
ing with D2-40. First, we selected five hot spot areas
with highly D2-40 positive vessels in peritumoral sec-
tions and intratumoral sections were identified by scan-
ning the sections at 40 X magnification. Next, the
number of D2-40 positive vessels was counted in ran-
domly selected three fields in each hot spot area at 200
X magnification [24]. The mean value for the three fields
was taken as the LVD. The 66 cases were divided into
two groups according to the mean LVD level, either
I-LVD or P-LVD group. Scoring and counting were per-
formed independently by two pathologists without
knowledge of clinicopathological data or survival of
patients.
Statistical analysis
Analyses were performed using the SPSS statistical software
program for Windows version 21 (SPSS Inc., Chicago, IL,
USA). Comparison of the means was performed using
Student’s t-test and one-way ANOVA, followed by Tukey’s
multiple comparison test for continuous variables. The
survival data for both groups were analyzed by means of
the Kaplan-Meier method and the log-rank test was used
for the assessment of the difference between the two
groups. Two-sided P <0.05 was considered a statistically
significant difference.
Results
Intratumoral and peritumoral lymphatic characteristics in
gastric cancer
The D2-40-positive lymphatic vessels had irregular morph-
ology and thin-walled lumens. Lymphatic vessels in gastric
tissues were mostly located in the layer of submucosa.
Intratumoral lymphatic vessels were usually collapsed,
small, and irregular in all intestinal and diffuse types (Fig. 1a
and b), but some non-collapsed lymphatics had open
lumens and occasionally contained invading tumor-cell
clusters (Fig. 2). The peritumoral lymphatic vessels were
enlarged with dilated lymphatic cavities, regardless of their
Lauren classification (Fig. 3a and b). Overall, the mean
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I-LVD was higher than the mean P-LVD (12.29 ± 4.35 vs.
11.01 ± 3.62 [±SD throughout], P = 0.025). In addition, the
mean I-LVD of the intestinal and diffuse subtypes was sig-
nificantly different (11.20 ± 3.06 vs. 13.27 ± 5.09, respect-
ively, P = 0.048). However, the P-LVD of the two subtypes
was not significantly different..
Correlations of I-LVD and P-LVD with clinicopathological
parameters and prognosis
The correlations of I-LVD and P-LVD with clinicopatho-
logical parameters are shown in Table 1. Neither I-LVD
nor P-LVD correlated with age, sex, extent of resection,
tumor location, or tumor size. In addition to the associ-
ation of I-LVD with the diffuse type of cancer, it was also
significantly associated with the undifferentiated type
(P = 0.021), tumor stage (T-stage; P = 0.024), LVI
(P = 0.004), tumor node metastasis (TNM) stage
(P = 0.029), and poor overall survival (P = 0.031; refer
also to Fig. 4 a and b). Although it failed to reach statis-
tical significance, the data showed a trend for I-LVD to
associate with node (N)-stage (P = 0.052). In comparison,
P-LVD had a significant correlation with LVI (P = 0.028),
Table 1 Correlation of LVD with clinicopathological parameters and survival
Factors (N) I-LVD P-LVD
mean ± SD P mean ± SD P
Age <60 (33) 12.60 ± 5.32 N.S. 10.52 ± 3.22 N.S.
>60 (33) 11.99 ± 3.15 11.53 ± 3.99
Sex Male (47) 12.31 ± 4.79 N.S. 11.06 ± 3.91 N.S.
Female (19) 12.24 ± 3.11 10.88 ± 2.83
Extent of resection Total gastrectomy (16) 13.78 ± 5.62 N.S. 12.36 ± 5.30 N.S.
Subtotal gastrectomy (50) 11.82 ± 3.81 10.59 ± 2.87
Tumor location Upper 1/3 (12) 12.01 ± 3.30 N.S. 11.74 ± 5.40 N.S.
Middle 1/3 (21) 13.49 ± 5.18 11.26 ± 3.63
Lower 1/3 (32) 12.33 ± 4.37 10.63 ± 2.92
Tumor size <5cm (36) 12.20 ± 4.98 N.S. 10.55 ± 3.61 N.S.
>5cm (30) 12.40 ± 3.53 11.56 ± 3.62
Lauren classification Intestinal type (31) 11.20 ± 3.06 0.048* 10.10 ± 2.74 N.S.
Diffuse type (35) 13.26 ± 5.09 11.55 ± 4.23
Differentiation Differentiated (31) 11.03 ± 2.80 0.021* 10.49 ± 2.74 N.S.
Undifferentiated (35) 13.41 ± 5.15 11.47 ± 4.25
Tumor stage (AJCC 7th ed.) T1 (18) 10.22 ± 3.53 0.024* 9.87 ± 3.55 N.S.
T2 (11)) 12.95 ± 4.09 11.70 ± 3.64
T3 (26) 12.23 ± 3.95 11.05 ± 3.74
T4 (11) 15.16 ± 5.37 12.18 ± 3.37
LVI Negative (37) 10.96 ± 3.80 0.004* 10.18 ± 3.71 0.028*
Positive (29) 13.99 ± 4.48 12.12 ± 3.28
Node stage (AJCC 7th ed.) N0 (36) 11.26 ± 3.84 0.052 10.00 ± 2.77 0.040*
N1 (3) 3.34 ± 2.20 10.25 ± 0.55
N2 (7) 13.51 ± 3.79 12.38 ± 1.84
N3 (20) 14.16 ± 5.00 12.67 ± 4.38
Tumor node metastasis stage (AJCC 7th ed.) I (20) 10.45 ± 3.93 0.029* 9.81 ± 3.02 0.061
II (30) 12.27 ± 3.58 10.88 ± 3.18
III (18) 14.17 ± 5.14 12.56 ± 4.48
DFS (month) LVD-Low (38) 57.82 ± 3.07 N.S. 59.31 ± 2.77 0.037*
LVD-High (28) 51.45 ± 4.84 51.21 ± 4.81
OS (month) LVD-Low (38) 61.70 ± 2.62 0.031* 60.06 ± 2.70 0.088
LVD-High (28) 52.60 ± 4.44 55.96 ± 4.14
LVI, lympho-vascular invasion; DFS, disease free survival; OS, overall survival
*, P <0.05; N.S., not significant; data are expressed as means ± SD
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N-stage (P = 0.040), poor disease-free survival (P = 0.037;
also refer to Fig. 5a), and a tendency for association with
TNM-stage (P = 0.061) and overall survival (P = 0.088,
Fig. 5b). Lauren classification, differentiation, and
T-stage were not correlated with P-LVD.
We suggest that these results are consistent with dif-
ferent biological roles for I-LVD and P-LVD in gastric
cancer. I-LVD was more closely correlated with depth of
invasion than it was with lymph node metastasis, while
P-LVD had a strong relationship with lymph node me-
tastasis rather than depth of invasion. Both parameters
correlated with TNM stage and oncological long-term
survival. Thus, both intratumoral lymphatics and peritu-
moral lymphatics may contribute to gastric cancer pro-
gression and prognosis but in different ways.
Discussion
A study by Padera and coworkers, with an in vivo animal
model, has conclusively established that peritumoral
lymphatics are predominantly responsible for the uptake
ability of cancer cells during metastasis [16]. However,
the role of intratumoral versus peritumoral lymphatics
Fig. 1 Intratumoral lympho-vascular density (I-LVD). a intestinal type, b diffuse type. Arrows indicate lymphatics
Fig. 2 Intratumoral lymphatics containing tumor (Lymphovascular invasion)
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in the pathology of primary human tumors [3, 5, 8, 12–15]
has not been so convincingly demonstrated. To date, there
have been seven studies comparing the values of I-LVD and
P-LVD in lymph node metastasis. In three of them, P-LVD
was more highly correlated with lymph node metastasis
and a poor prognosis than was I-LVD [17–19], although
other studies do not confirm the correlation. Lee et al. [25]
reported that I-LVD in early gastric cancer was related to
lymph node metastasis, while P-LVD was not, in either
early or late stages of the disease. Gao et al. [26] found that
both I-LVD and P-LVD were associated with lymph node
metastasis in early gastric cancer, but only P-LVD was cor-
related with it in advanced stages. Raica et al. [21] reported
that both I- and P-LVD were related to lymph node metas-
tasis and a poor prognosis, but in yet another study, there
was no correlation between LVD in either location and
lymph node metastasis or prognosis [22]. Based on our re-
sults, we suggest that P-LVD is more important in lymph
node metastasis than is I-LVD. Some association of I-LVD
with lymph node metastasis was indicated and although it
failed to reach statistical significance (P = 0.052), the data
do not exclude the possibility that I-LVD influences lymph
node metastasis.
The distribution of lymphatic channels in tumors also
appears to vary by the organ affected. Few lymphatic
channels in breast cancers have been identified in intra-
tumoral areas, with the majority located around the
tumor periphery [27]. However, increased LVD within
the tumor and in peritumoral areas has been observed
in cutaneous melanoma [28]. In our study, I-LVD was
generally higher than P-LVD, in agreement with Lee
et al. [20]. In addition, I-LVD was positively correlated
with the depth of tumor invasion. These findings
indicate that intratumoral lymphatic channels are the
product of neovascularization by tumor cells rather than
simple entrapment of pre-existing, normal lymphatic
channels. LVD in both locations was correlated with
TNM stage and led to a poor prognosis. This may
Fig. 3 Peritumoral lympho-vascular density (P-LVD). a intestinal type, b diffuse type. Arrows indicate lymphatics
Fig. 4 Survival curve according to the intratumoral lympho-vascular density (I-LVD). a Disease-free survival, b overall survival
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indicate that high LVD in either location contributes to
gastric cancer progression, but that they act in different
manners.
The results indicate a correlation between P-LVD and
TNM stage although they did not quite reach signifi-
cance (P = 0.061). Likewise, we observed some clear
trends in our analyses of long-term survival, but the stat-
istical analysis requires that they should be interpreted
cautiously. Nonetheless, the results are intriguing and
we believe the failure to detect clear differences is due to
the small sample size and that both I-LVD and P-LVD
are important in cancer progression and the poor prog-
nosis of gastric cancer patients.
Angiogenesis inhibitor (Avastin®, bevacizumab) has
been used as a molecular targeting agent in the treat-
ment of colon cancer and renal cell carcinoma [29, 30].
Although it was ineffective in the treatment of gastric
cancer in the AVAGAST trial, the results cannot be
considered conclusive because the study was analyzed
without the biomarker’s classification [31]. In addition,
the REGARD trial showed that the VEGFR-2 inhibitor
prolonged the survival of patients with advanced gastric
cancer [32]. Similar to the growing awareness of the
importance of angiogenesis, awareness of the importance
of lymphangiogenesis is emerging. In particular, in the
case of tumors in which prognosis is dependent on
lymph node status and in which lymph node metastasis
is a major biological process leading to distant tumor
propagation, lymphangiogenesis inhibition is of utmost
clinical importance. Thus, continued research on
lymphangiogenesis is critical.
We have some limitations to draw a solid conclusion
in this study. One of them is a selection bias. We
selected 66 cases arbitrarily from 365 patients for IHC
staining, although we matched TNM stages according to
Lauren’s classification to remove the effect of tumor
aggressiveness. Small samples must be one of limitations
too. However, our results could suggest some conceptual
important points. In this study, we used D2-40 for stain-
ing of lymphatics. D2-40 is a commercially available
monoclonal antibody directed against human podopla-
nin a transmembrane mucoprotein that is expressed in
lymphatic endothelial cells. Many studies indicate that
D2-40 is specific for lymphatic invasion and LVD in
human cancers, including gastric cancer [33–37]. How-
ever, some studies reported that D2-40 could be
expressed in other tissues such as seminoma, epithelioid,
adrenal cortical tumor, Kaposi sarcoma, adnexal tumors
of the skin [38–43]. D2-40 immunoreactivity is restricted
to lymphatic endothelium, not blood vessels. Therefore,
the conjunction with specific vascular marker, such as
CD31 or CD34, which highlights both blood vessel and
lymphatic endothelium was suggested to detect
lymphatics specifically [44]. Wang et al. performed
immune-staining of lymphatics with D2-40 and CD31 in
gastric cancer tissue and showed that D2-40 showed exclu-
sively stained lymphatic endothelium [18]. Consistently, our
study also demonstrated that D2-40 was a good lymphatic
endothelial maker in gastric cancer tissue.
In conclusion, although we should be cautious due to
the small sample size, P-LVD might have a more import-
ant role in lymph node metastasis than I-LVD, while
I-LVD was associated with depth of tumor invasion.
Collectively, high LVD in both locations contributed to
gastric cancer progression and prognosis; thus, lymphan-
giogenesis inhibition should be considered an important
target of therapy for treatment of gastric cancer.
Conclusions
We conclude that P-LVD was significantly associated
with lymph node metastasis, while I-LVD was more
associated with depth of tumor invasion. However, both
LVDs contributed to gastric cancer progression and
prognosis.
Fig. 5 Survival curve according to the peritumoral lympho-vascular density (P-LVD). a Disease-free survival, b overall survival
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